<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="id">
	<id>https://wiki.unissula.ac.id/index.php?action=history&amp;feed=atom&amp;title=Antidepresan</id>
	<title>Antidepresan - Riwayat revisi</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.unissula.ac.id/index.php?action=history&amp;feed=atom&amp;title=Antidepresan"/>
	<link rel="alternate" type="text/html" href="https://wiki.unissula.ac.id/index.php?title=Antidepresan&amp;action=history"/>
	<updated>2026-09-16T14:19:09Z</updated>
	<subtitle>Riwayat revisi halaman ini di wiki</subtitle>
	<generator>MediaWiki 1.46.0</generator>
	<entry>
		<id>https://wiki.unissula.ac.id/index.php?title=Antidepresan&amp;diff=27609&amp;oldid=prev</id>
		<title>Maintenance script: Presentation V4: sitasi, referensi, Math, Wikimedia Commons, dan atribusi</title>
		<link rel="alternate" type="text/html" href="https://wiki.unissula.ac.id/index.php?title=Antidepresan&amp;diff=27609&amp;oldid=prev"/>
		<updated>2026-08-29T18:13:37Z</updated>

		<summary type="html">&lt;p&gt;Presentation V4: sitasi, referensi, Math, Wikimedia Commons, dan atribusi&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw-interface=&quot;&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;id&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Revisi sebelumnya&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revisi per 29 Agustus 2026 18.13&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Baris 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Baris 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&#039;&#039;&#039;Antidepresan&#039;&#039;&#039; adalah sebuah [[obat]] yang digunakan untuk mengobati [[gangguan depresi mayor]], beberapa [[gangguan kecemasan]], beberapa kondisi [[nyeri kronis]], dan untuk membantu mengelola beberapa [[kecanduan]]. [[Efek samping]] umum dari antidepresan termasuk [[Xerostomia|mulut kering]], [[penambahan berat badan]], [[pusing]], [[sakit kepala]], dan [[disfungsi seksual]].&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;[[File:Venlafaxine_structure.svg|thumb|right|280px|Venlafaxine structure]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&#039;&#039;&#039;Antidepresan&#039;&#039;&#039; adalah sebuah [[obat]] yang digunakan untuk mengobati [[gangguan depresi mayor]], beberapa [[gangguan kecemasan]], beberapa kondisi [[nyeri kronis]], dan untuk membantu mengelola beberapa [[kecanduan]].&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;ref&amp;gt;Leigh Jennings. &#039;&#039;Clinical psychopharmacology for neurologists: a practical guide&#039;&#039;. Springer. 2018. hlm. 45–71. doi:10.1007/978-3-319-74604-3_4. ISBN 978-3-319-74602-9.&amp;lt;/ref&amp;gt; &lt;/ins&gt;[[Efek samping]] umum dari antidepresan termasuk [[Xerostomia|mulut kering]], [[penambahan berat badan]], [[pusing]], [[sakit kepala]], dan [[disfungsi seksual]].&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;ref&amp;gt;&#039;&#039;Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases&#039;&#039;. &#039;&#039;International Journal of Risk &amp;amp; Safety in Medicine&#039;&#039;. May 2018. Vol. 29 (3). hlm. 125–134. doi:10.3233/JRS-180744.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Audrey S. Bahrick. &#039;&#039;Persistence of Sexual Dysfunction Side Effects after Discontinuation of Antidepressant Medications: Emerging Evidence&#039;&#039;. &#039;&#039;The Open Psychology Journal&#039;&#039;. 2008. Vol. 1. hlm. 42–50. doi:10.2174/1874350100801010042.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[https://kclpure.kcl.ac.uk/portal/en/publications/strategies-for-managing-sexual-dysfunction-induced-by-antidepressant-medication(5f0f0033-e139-42cc-9590-d3b5cad1bb25).html Strategies for managing sexual dysfunction induced by antidepressant medication]. &#039;&#039;The Cochrane Database of Systematic Reviews&#039;&#039;. May 2013. Vol. 5 (5). hlm. CD003382. doi:10.1002/14651858.CD003382.pub3.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&#039;&#039;Sexual dysfunction, depression, and the impact of antidepressants&#039;&#039;. &#039;&#039;Journal of Clinical Psychopharmacology&#039;&#039;. April 2009. Vol. 29 (2). hlm. 157–64. doi:10.1097/jcp.0b013e31819c76e9.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;[https://www.ema.europa.eu/en/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-13-16-may-2019-prac_en.pdf Serotonin and noradrenaline reuptake inhibitors (SNRI); selective serotonin reuptake inhibitors (SSRI) – Persistent sexual dysfunction after drug withdrawal ](EPITT no 19277), 11 June 20191, EMA/PRAC/265221/2019, Pharmacovigilance Risk Assessment Committee (PRAC)&amp;lt;/ref&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Sebagian besar jenis antidepresan biasanya aman dikonsumsi, tetapi dapat menyebabkan meningkatnya pikiran untuk bunuh diri ketika dikonsumsi oleh anak-anak, remaja, dan dewasa muda. Sindrom penghentian dapat terjadi setelah menghentikan antidepresan yang menyerupai depresi berulang.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Sebagian besar jenis antidepresan biasanya aman dikonsumsi, tetapi dapat menyebabkan meningkatnya pikiran untuk bunuh diri ketika dikonsumsi oleh anak-anak, remaja, dan dewasa muda. Sindrom penghentian dapat terjadi setelah menghentikan antidepresan yang menyerupai depresi berulang.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l26&quot;&gt;Baris 26:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Baris 28:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;===&amp;#039;&amp;#039;Serotonin–norepinephrine–dopamine reuptake inhibitors&amp;#039;&amp;#039; (SNDRIs)===&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;===&amp;#039;&amp;#039;Serotonin–norepinephrine–dopamine reuptake inhibitors&amp;#039;&amp;#039; (SNDRIs)===&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Toludesvenlafaksin]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Toludesvenlafaksin]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Nefazodon]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Nefazodon]]&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;ref&amp;gt;&#039;&#039;Pharmacological profile of antidepressants and related compounds at human monoamine transporters&#039;&#039;. &#039;&#039;European Journal of Pharmacology&#039;&#039;. December 1997. Vol. 340 (2-3). hlm. 249–258. doi:10.1016/s0014-2999(97)01393-9.&amp;lt;/ref&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;===&amp;#039;&amp;#039;Serotonin modulators and stimulators&amp;#039;&amp;#039; (SMSs)===&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;===&amp;#039;&amp;#039;Serotonin modulators and stimulators&amp;#039;&amp;#039; (SMSs)===&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l44&quot;&gt;Baris 44:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Baris 46:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Viloksazin]] – juga merupakan antagonis reseptor 5-HT&amp;lt;sub&amp;gt;2B&amp;lt;/sub&amp;gt; dan agonis reseptor 5-5-HT&amp;lt;sub&amp;gt;2C&amp;lt;/sub&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Viloksazin]] – juga merupakan antagonis reseptor 5-HT&amp;lt;sub&amp;gt;2B&amp;lt;/sub&amp;gt; dan agonis reseptor 5-5-HT&amp;lt;sub&amp;gt;2C&amp;lt;/sub&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Hanya di luar label:&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Hanya di luar label:&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Atomoksetin]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Atomoksetin]]&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;ref&amp;gt;[https://www.ncbi.nlm.nih.gov/books/NBK493234/ StatPearls [Internet]]. StatPearls Publishing. March 2023.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&#039;&#039;The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects&#039;&#039;. &#039;&#039;CNS Neurosci Ther&#039;&#039;. December 2011. Vol. 17 (6). hlm. 723–32. doi:10.1111/j.1755-5949.2010.00217.x.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&#039;&#039;A systematic review of augmentation strategies for patients with major depressive disorder&#039;&#039;. &#039;&#039;Psychopharmacol Bull&#039;&#039;. 2009. Vol. 42 (3). hlm. 57–90.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&#039;&#039;A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder&#039;&#039;. &#039;&#039;J Clin Psychiatry&#039;&#039;. September 2014. Vol. 75 (9). hlm. 1010–8. doi:10.4088/JCP.13r08851.&amp;lt;/ref&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;===&amp;#039;&amp;#039;Norepinephrine–dopamine reuptake inhibitors&amp;#039;&amp;#039; (NDRIs)===&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;===&amp;#039;&amp;#039;Norepinephrine–dopamine reuptake inhibitors&amp;#039;&amp;#039; (NDRIs)===&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Bupropion]] – juga merupakan antagonis non-kompetitif reseptor asetilkolin nikotinat&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Bupropion]] – juga merupakan antagonis non-kompetitif reseptor asetilkolin nikotinat&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;ref&amp;gt;&#039;&#039;Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion&#039;&#039;. &#039;&#039;Int. Rev. Neurobiol&#039;&#039;. 2009. Vol. 88. hlm. 223–55. doi:10.1016/S0074-7742(09)88009-4. ISBN 9780123745040.&amp;lt;/ref&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Hanya di luar label:&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Hanya di luar label:&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Amfetamin]] – sebenarnya agen pelepas norepinefrin-dopamin (NDRA)&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Amfetamin]] – sebenarnya agen pelepas norepinefrin-dopamin (NDRA)&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;ref&amp;gt;&#039;&#039;Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs&#039;&#039;. &#039;&#039;Biochem. Pharmacol&#039;&#039;. 2015. Vol. 95 (2). hlm. 81–97. doi:10.1016/j.bcp.2015.03.011.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&#039;&#039;A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder&#039;&#039;. &#039;&#039;J Clin Psychiatry&#039;&#039;. September 2014. Vol. 75 (9). hlm. 1010–8. doi:10.4088/JCP.13r08851.&amp;lt;/ref&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Metilfenidat]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Metilfenidat]]&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;ref&amp;gt;&#039;&#039;Methylphenidate: its pharmacology and uses&#039;&#039;. &#039;&#039;Mayo Clin. Proc&#039;&#039;. 2000. Vol. 75 (7). hlm. 711–21. doi:10.4065/75.7.711.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&#039;&#039;Methylphenidate: established and expanding roles in symptom management&#039;&#039;. &#039;&#039;Am J Hosp Palliat Care&#039;&#039;. 2012. Vol. 29 (6). hlm. 483–90. doi:10.1177/1049909111427029.&amp;lt;/ref&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Modafinil]] – sebenarnya penghambat pengambilan kembali dopamin selektif ditambah tindakan lainnya&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Modafinil]] – sebenarnya penghambat pengambilan kembali dopamin selektif ditambah tindakan lainnya&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;ref&amp;gt;&#039;&#039;The role of eugeroics in the treatment of affective disorders&#039;&#039;. &#039;&#039;Psychiatr Pol&#039;&#039;. February 2020. Vol. 54 (1). hlm. 21–33. doi:10.12740/PP/OnlineFirst/90687.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&#039;&#039;Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence&#039;&#039;. &#039;&#039;Eur Neuropsychopharmacol&#039;&#039;. May 2017. Vol. 27 (5). hlm. 423–441. doi:10.1016/j.euroneuro.2017.03.003.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&#039;&#039;Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: A meta-analysis of randomized controlled trials&#039;&#039;. &#039;&#039;Bipolar Disord&#039;&#039;. March 2020. Vol. 22 (2). hlm. 109–120. doi:10.1111/bdi.12859.&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&#039;&#039;Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis&#039;&#039;. &#039;&#039;Acta Psychiatr Scand&#039;&#039;. June 2017. Vol. 135 (6). hlm. 527–538. doi:10.1111/acps.12712.&amp;lt;/ref&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Dihentikan/ditarik:&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Dihentikan/ditarik:&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l102&quot;&gt;Baris 102:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Baris 104:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;===&amp;#039;&amp;#039;Monoamine Oxidase Inhibitors&amp;#039;&amp;#039; (MAOIs)===&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;===&amp;#039;&amp;#039;Monoamine Oxidase Inhibitors&amp;#039;&amp;#039; (MAOIs)===&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;====Tidak dapat diubah====&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;====Tidak dapat diubah====&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-added&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;;Nonselektif&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;;Nonselektif&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Fenelzin]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Fenelzin]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l125&quot;&gt;Baris 125:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Baris 126:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;====Dapat diubah====&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;====Dapat diubah====&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-added&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;;Nonselektif&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;;Nonselektif&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l145&quot;&gt;Baris 145:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Baris 145:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;====Dicampur====&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;====Dicampur====&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-added&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;;Nonselektif&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;;Nonselektif&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Bifemelan]] – RIMA, penghambat MAO-B yang tidak dapat diubah, dan NRI lemah&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Bifemelan]] – RIMA, penghambat MAO-B yang tidak dapat diubah, dan NRI lemah&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l159&quot;&gt;Baris 159:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Baris 158:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Agomelatin]] – [[Antagonis reseptor]] 5-HT&amp;lt;sub&amp;gt;2C&amp;lt;/sub&amp;gt; dan agonis reseptor MT&amp;lt;sub&amp;gt;1&amp;lt;/sub&amp;gt; dan MT&amp;lt;sub&amp;gt;2&amp;lt;/sub&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Agomelatin]] – [[Antagonis reseptor]] 5-HT&amp;lt;sub&amp;gt;2C&amp;lt;/sub&amp;gt; dan agonis reseptor MT&amp;lt;sub&amp;gt;1&amp;lt;/sub&amp;gt; dan MT&amp;lt;sub&amp;gt;2&amp;lt;/sub&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Allopregnanolon]] – Modulator alosterik positif reseptor GABA&amp;lt;sub&amp;gt;A&amp;lt;/sub&amp;gt; – disetujui untuk [[depresi pascapersalinan]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Allopregnanolon]] – Modulator alosterik positif reseptor GABA&amp;lt;sub&amp;gt;A&amp;lt;/sub&amp;gt; – disetujui untuk [[depresi pascapersalinan]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Esketamin]] – antagonis reseptor NMDA non-kompetitif, tindakan lain&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Esketamin]] – antagonis reseptor NMDA non-kompetitif, tindakan lain&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;ref&amp;gt;[https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243lbl.pdf SPRAVATO™ (esketamine) nasal spray FDA label]. Food and Drug Administration. 5 March 2019.&amp;lt;/ref&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Gepiron]] – Agonis parsial reseptor 5-HT&amp;lt;sub&amp;gt;1A&amp;lt;/sub&amp;gt; dan antagonis reseptor α&amp;lt;sub&amp;gt;2&amp;lt;/sub&amp;gt;-adrenergik&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Gepiron]] – Agonis parsial reseptor 5-HT&amp;lt;sub&amp;gt;1A&amp;lt;/sub&amp;gt; dan antagonis reseptor α&amp;lt;sub&amp;gt;2&amp;lt;/sub&amp;gt;-adrenergik&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Opipramol]] — Agonis reseptor σ&amp;lt;sub&amp;gt;1&amp;lt;/sub&amp;gt;, tindakan lain&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Opipramol]] — Agonis reseptor σ&amp;lt;sub&amp;gt;1&amp;lt;/sub&amp;gt;, tindakan lain&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l165&quot;&gt;Baris 165:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Baris 164:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;====Hanya di luar label====&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;====Hanya di luar label====&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Ketamin]] – antagonis reseptor NMDA non-kompetitif&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Ketamin]] – antagonis reseptor NMDA non-kompetitif&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;ref&amp;gt;&#039;&#039;Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications&#039;&#039;. &#039;&#039;BMC Med Ethics&#039;&#039;. 2016. Vol. 17. hlm. 4. doi:10.1186/s12910-016-0087-3.&amp;lt;/ref&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Pramipeksol]] - Agonis [[Reseptor (biokimia)|reseptor]] dopamin D2, D3, dan D4&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Pramipeksol]] - Agonis [[Reseptor (biokimia)|reseptor]] dopamin D2, D3, dan D4&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;ref&amp;gt;&#039;&#039;Pramipexole Augmentation for Treatment-Resistant Unipolar and Bipolar Depression in the Real World: A Systematic Review and Meta-Analysis&#039;&#039;. &#039;&#039;Life&#039;&#039;. April 2023. Vol. 13 (4). hlm. 1043. doi:10.3390/life13041043.&amp;lt;/ref&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;** Agonis dopamin tidak dianjurkan karena kecenderungannya memfasilitasi perkembangan kecanduan bahkan pada individu yang tidak memiliki riwayat perilaku tersebut.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;** Agonis dopamin tidak dianjurkan karena kecenderungannya memfasilitasi perkembangan kecanduan bahkan pada individu yang tidak memiliki riwayat perilaku tersebut.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l199&quot;&gt;Baris 199:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Baris 198:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;====Antipsikotik tipikal====&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;====Antipsikotik tipikal====&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;;Hanya di luar label&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;;Hanya di luar label&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Trifluoperazin]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Trifluoperazin]]&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;ref&amp;gt;&#039;&#039;Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants: Are the Risks Worth the Benefits?&#039;&#039;. &#039;&#039;Psychiatr. Clin. North Am&#039;&#039;. 2016. Vol. 39 (3). hlm. 477–86. doi:10.1016/j.psc.2016.04.008.&amp;lt;/ref&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;====Lainnya====&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;====Lainnya====&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-added&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;;Hanya di luar label&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;;Hanya di luar label&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Buspiron]] – Agonis parsial reseptor 5-HT&amp;lt;sub&amp;gt;1A&amp;lt;/sub&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Buspiron]] – Agonis parsial reseptor 5-HT&amp;lt;sub&amp;gt;1A&amp;lt;/sub&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l216&quot;&gt;Baris 216:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Baris 214:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Tranilsipromin/trifluoperazin]] – MAOI dan kombinasi antipsikotik tipikal&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Tranilsipromin/trifluoperazin]] – MAOI dan kombinasi antipsikotik tipikal&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Bupropion/dekstrometorfan]] – antagonis reseptor NMDA non-kompetitif, agonis reseptor σ&amp;lt;sub&amp;gt;1&amp;lt;/sub&amp;gt;, SNRI, NDRI, tindakan lainnya&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Bupropion/dekstrometorfan]] – antagonis reseptor NMDA non-kompetitif, agonis reseptor σ&amp;lt;sub&amp;gt;1&amp;lt;/sub&amp;gt;, SNRI, NDRI, tindakan lainnya&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-added&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;== Referensi ==&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-added&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-added&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Pranala luar ==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Pranala luar ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-added&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;*&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;== Referensi ==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;references /&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;== Sumber dan atribusi ==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Sumber &lt;/del&gt;dan &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;atribusi ==&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Konten artikel ini diadaptasi dari [https://id.wikipedia.org/w/index.php?title&lt;/ins&gt;=&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Antidepresan&amp;amp;oldid&lt;/ins&gt;=&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;29110699 Wikipedia bahasa Indonesia], revisi 29110699 (2026-04-07T11:03:24Z), yang tersedia berdasarkan lisensi Creative Commons Atribusi-BerbagiSerupa (CC BY-SA). Gambar pada artikel ini bersumber dari Wikimedia Commons &lt;/ins&gt;dan &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;mengikuti ketentuan lisensi masing-masing berkas. Mohon gunakan konten dan media secara bijak serta sesuai dengan ketentuan lisensi yang berlaku.&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Konten artikel ini diadaptasi dari [https://id.wikipedia.org/w/index.php?title=Antidepresan&amp;amp;oldid=29110699 Wikipedia bahasa Indonesia], revisi 29110699 (2026&lt;/del&gt;-&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;04&lt;/del&gt;-&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;07T11:03:24Z), yang tersedia berdasarkan lisensi Creative Commons Atribusi&lt;/del&gt;-&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;BerbagiSerupa (CC BY&lt;/del&gt;-&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;SA). Mohon gunakan konten ini secara bijak serta sesuai dengan ketentuan lisensi yang berlaku.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;!&lt;/ins&gt;-- &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;WIKI_UNISSULA_PRESENTATION_V4 &lt;/ins&gt;--&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Maintenance script</name></author>
	</entry>
	<entry>
		<id>https://wiki.unissula.ac.id/index.php?title=Antidepresan&amp;diff=27211&amp;oldid=prev</id>
		<title>Maintenance script: Impor teks terkontrol dari Wikipedia bahasa Indonesia; revisi 29110699; atribusi sumber disertakan.</title>
		<link rel="alternate" type="text/html" href="https://wiki.unissula.ac.id/index.php?title=Antidepresan&amp;diff=27211&amp;oldid=prev"/>
		<updated>2026-08-29T17:48:25Z</updated>

		<summary type="html">&lt;p&gt;Impor teks terkontrol dari Wikipedia bahasa Indonesia; revisi 29110699; atribusi sumber disertakan.&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Halaman baru&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;#039;&amp;#039;&amp;#039;Antidepresan&amp;#039;&amp;#039;&amp;#039; adalah sebuah [[obat]] yang digunakan untuk mengobati [[gangguan depresi mayor]], beberapa [[gangguan kecemasan]], beberapa kondisi [[nyeri kronis]], dan untuk membantu mengelola beberapa [[kecanduan]]. [[Efek samping]] umum dari antidepresan termasuk [[Xerostomia|mulut kering]], [[penambahan berat badan]], [[pusing]], [[sakit kepala]], dan [[disfungsi seksual]].&lt;br /&gt;
&lt;br /&gt;
Sebagian besar jenis antidepresan biasanya aman dikonsumsi, tetapi dapat menyebabkan meningkatnya pikiran untuk bunuh diri ketika dikonsumsi oleh anak-anak, remaja, dan dewasa muda. Sindrom penghentian dapat terjadi setelah menghentikan antidepresan yang menyerupai depresi berulang.&lt;br /&gt;
&lt;br /&gt;
== Jenis ==&lt;br /&gt;
Berikut merupakan jenis obat antidepresan:&lt;br /&gt;
===&amp;#039;&amp;#039;Selective Serotonin Re-uptake Inhibitor&amp;#039;&amp;#039; (SSRIs)===&lt;br /&gt;
* [[Sitalopram]]&lt;br /&gt;
* [[Esitalopram]]&lt;br /&gt;
* [[Fluoksetin]]&lt;br /&gt;
* [[Fluvoksamin]]&lt;br /&gt;
* [[Paroksetin]]&lt;br /&gt;
* [[Sertralin]]&lt;br /&gt;
&lt;br /&gt;
Dihentikan/ditarik:&lt;br /&gt;
* [[Indalpin]]&lt;br /&gt;
* [[Zimelidin]]&lt;br /&gt;
&lt;br /&gt;
===&amp;#039;&amp;#039;Serotonin and Norepinephrine Reuptake Inhibitors&amp;#039;&amp;#039; (SNRIs)===&lt;br /&gt;
* [[Desvenlafaksin]]&lt;br /&gt;
* [[Duloksetin]]&lt;br /&gt;
* [[Levomilnacipran]]&lt;br /&gt;
* [[Milnacipran]]&lt;br /&gt;
* [[Venlafaksin]]&lt;br /&gt;
&lt;br /&gt;
===&amp;#039;&amp;#039;Serotonin–norepinephrine–dopamine reuptake inhibitors&amp;#039;&amp;#039; (SNDRIs)===&lt;br /&gt;
* [[Toludesvenlafaksin]]&lt;br /&gt;
* [[Nefazodon]]&lt;br /&gt;
&lt;br /&gt;
===&amp;#039;&amp;#039;Serotonin modulators and stimulators&amp;#039;&amp;#039; (SMSs)===&lt;br /&gt;
* [[Vilazodon]]&lt;br /&gt;
* [[Vortioksetin]]&lt;br /&gt;
&lt;br /&gt;
===&amp;#039;&amp;#039;Serotonin antagonist and reuptake inhibitors&amp;#039;&amp;#039; (SARIs)===&lt;br /&gt;
* [[Nefazodon]] (Dihentikan/ditarik di banyak negara)&lt;br /&gt;
* [[Trazodon]]&lt;br /&gt;
&lt;br /&gt;
Dihentikan/ditarik:&lt;br /&gt;
* [[Etoperidon]]&lt;br /&gt;
&lt;br /&gt;
===&amp;#039;&amp;#039;Norepinephrine reuptake inhibitors&amp;#039;&amp;#039; (NRIs)===&lt;br /&gt;
* [[Reboksetin]]&lt;br /&gt;
* [[Teniloksazin]] – juga merupakan antagonis reseptor 5-HT&amp;lt;sub&amp;gt;2A&amp;lt;/sub&amp;gt;&lt;br /&gt;
* [[Viloksazin]] – juga merupakan antagonis reseptor 5-HT&amp;lt;sub&amp;gt;2B&amp;lt;/sub&amp;gt; dan agonis reseptor 5-5-HT&amp;lt;sub&amp;gt;2C&amp;lt;/sub&amp;gt;&lt;br /&gt;
Hanya di luar label:&lt;br /&gt;
* [[Atomoksetin]]&lt;br /&gt;
&lt;br /&gt;
===&amp;#039;&amp;#039;Norepinephrine–dopamine reuptake inhibitors&amp;#039;&amp;#039; (NDRIs)===&lt;br /&gt;
* [[Bupropion]] – juga merupakan antagonis non-kompetitif reseptor asetilkolin nikotinat&lt;br /&gt;
&lt;br /&gt;
Hanya di luar label:&lt;br /&gt;
* [[Amfetamin]] – sebenarnya agen pelepas norepinefrin-dopamin (NDRA)&lt;br /&gt;
* [[Metilfenidat]]&lt;br /&gt;
* [[Modafinil]] – sebenarnya penghambat pengambilan kembali dopamin selektif ditambah tindakan lainnya&lt;br /&gt;
&lt;br /&gt;
Dihentikan/ditarik:&lt;br /&gt;
* [[Amineptin]]&lt;br /&gt;
* [[Nomifensin]]&lt;br /&gt;
&lt;br /&gt;
===Antidepresan trisiklik===&lt;br /&gt;
* [[Amitriptilin]]&lt;br /&gt;
* [[Amitriptilinoksida]]&lt;br /&gt;
* [[Desipramin]]&lt;br /&gt;
* [[Dibenzepin]]&lt;br /&gt;
* [[Dimetakrin]]&lt;br /&gt;
* [[Dosulepin]]&lt;br /&gt;
* [[Doksepin]]&lt;br /&gt;
* [[Imipramin]]&lt;br /&gt;
* [[Klomipramin]]&lt;br /&gt;
* [[Lofepramin]]&lt;br /&gt;
* [[Melitrasen]]&lt;br /&gt;
* [[Nitroksazepin]]&lt;br /&gt;
* [[Nortriptilin]]&lt;br /&gt;
* [[Noksiptilin]]&lt;br /&gt;
* [[Pipofezin]]&lt;br /&gt;
* [[Protriptilin]]&lt;br /&gt;
* [[Trimipramin]]&lt;br /&gt;
&lt;br /&gt;
[[Opipramol]], [[tianeptin]], dan [[amineptin]] (dihentikan) secara kimiawi adalah TCA tetapi secara [[farmakodinamika]] atipikal, dan oleh karena itu dikelompokkan di tempat lain.&lt;br /&gt;
&lt;br /&gt;
Dihentikan/ditarik:&lt;br /&gt;
* [[Butriptilin]]&lt;br /&gt;
* [[Demeksiptilin]]&lt;br /&gt;
* [[Fluasizin]]&lt;br /&gt;
* [[Imipraminoksida]]&lt;br /&gt;
* [[Iprindol]]&lt;br /&gt;
* [[Metapramin]]&lt;br /&gt;
* [[Propizepin]]&lt;br /&gt;
* [[Kuinupramin]]&lt;br /&gt;
* [[Tiazesim]] – sebenarnya bukan TCA tapi antidepresan mirip trisiklik&lt;br /&gt;
* [[Tofenasin]] – sebenarnya bukan TCA tapi antidepresan mirip trisiklik&lt;br /&gt;
&lt;br /&gt;
===Antidepresan tetrasiklik===&lt;br /&gt;
* [[Amoksapin]]&lt;br /&gt;
* [[Maprotilin]]&lt;br /&gt;
* [[Mianserin]]&lt;br /&gt;
* [[Mirtazapin]]&lt;br /&gt;
* [[Setiptilin]]&lt;br /&gt;
&lt;br /&gt;
Mianserin, mirtazapin, dan setiptilin juga kadang-kadang digambarkan sebagai antidepresan noradrenergik dan serotonergik spesifik (NaSSA).&lt;br /&gt;
&lt;br /&gt;
===&amp;#039;&amp;#039;Monoamine Oxidase Inhibitors&amp;#039;&amp;#039; (MAOIs)===&lt;br /&gt;
====Tidak dapat diubah====&lt;br /&gt;
&lt;br /&gt;
;Nonselektif&lt;br /&gt;
* [[Fenelzin]]&lt;br /&gt;
* [[Isokarboksazid]]&lt;br /&gt;
* [[Tranilsipromin]]&lt;br /&gt;
&lt;br /&gt;
Dihentikan/ditarik:&lt;br /&gt;
&lt;br /&gt;
* [[Benmoksin]]&lt;br /&gt;
* [[Feniprazin]]&lt;br /&gt;
* [[Fenoksipropazin]]&lt;br /&gt;
* [[Iproklozid]]&lt;br /&gt;
* [[Iproniazid]]&lt;br /&gt;
* [[Mebanazin]]&lt;br /&gt;
* [[Nialamida]]&lt;br /&gt;
* [[Oktamoksin]]&lt;br /&gt;
* [[Pivhidrazin]]&lt;br /&gt;
* [[Safrazin]]&lt;br /&gt;
&lt;br /&gt;
;Selektif untuk MAO-B&lt;br /&gt;
* [[Selegilin]]&lt;br /&gt;
&lt;br /&gt;
====Dapat diubah====&lt;br /&gt;
&lt;br /&gt;
;Nonselektif&lt;br /&gt;
&lt;br /&gt;
Dihentikan/ditarik:&lt;br /&gt;
&lt;br /&gt;
* [[Karoksazon]]&lt;br /&gt;
;Selektif untuk MAO-A&lt;br /&gt;
* [[Metralindol]]&lt;br /&gt;
* [[Moklobemida]]&lt;br /&gt;
* [[Pirlindol]]&lt;br /&gt;
&lt;br /&gt;
Obat-obatan ini kadang-kadang digambarkan sebagai penghambat MAO-A yang dapat diubah (RIMA).&lt;br /&gt;
&lt;br /&gt;
Dihentikan/ditarik:&lt;br /&gt;
&lt;br /&gt;
* [[Eprobemid]]&lt;br /&gt;
* [[Minaprin]]&lt;br /&gt;
* [[Toloksaton]]&lt;br /&gt;
&lt;br /&gt;
====Dicampur====&lt;br /&gt;
&lt;br /&gt;
;Nonselektif&lt;br /&gt;
* [[Bifemelan]] – RIMA, penghambat MAO-B yang tidak dapat diubah, dan NRI lemah&lt;br /&gt;
&lt;br /&gt;
===Antipsikotik atipikal===&lt;br /&gt;
* [[Amisulprida]] – disetujui dalam dosis rendah sebagai monoterapi untuk [[Distimia|depresi persisten]]&lt;br /&gt;
* [[Kuetiapin]] – disetujui sebagai monoterapi untuk depresi bipolar&lt;br /&gt;
* [[Lumateperon]] – disetujui sebagai monoterapi untuk depresi bipolar&lt;br /&gt;
* [[Lurasidon]] – disetujui sebagai monoterapi untuk depresi bipolar&lt;br /&gt;
&lt;br /&gt;
===Lainnya===&lt;br /&gt;
====Dipasarkan====&lt;br /&gt;
* [[Agomelatin]] – [[Antagonis reseptor]] 5-HT&amp;lt;sub&amp;gt;2C&amp;lt;/sub&amp;gt; dan agonis reseptor MT&amp;lt;sub&amp;gt;1&amp;lt;/sub&amp;gt; dan MT&amp;lt;sub&amp;gt;2&amp;lt;/sub&amp;gt;&lt;br /&gt;
* [[Allopregnanolon]] – Modulator alosterik positif reseptor GABA&amp;lt;sub&amp;gt;A&amp;lt;/sub&amp;gt; – disetujui untuk [[depresi pascapersalinan]]&lt;br /&gt;
* [[Esketamin]] – antagonis reseptor NMDA non-kompetitif, tindakan lain&lt;br /&gt;
* [[Gepiron]] – Agonis parsial reseptor 5-HT&amp;lt;sub&amp;gt;1A&amp;lt;/sub&amp;gt; dan antagonis reseptor α&amp;lt;sub&amp;gt;2&amp;lt;/sub&amp;gt;-adrenergik&lt;br /&gt;
* [[Opipramol]] — Agonis reseptor σ&amp;lt;sub&amp;gt;1&amp;lt;/sub&amp;gt;, tindakan lain&lt;br /&gt;
* [[Tianeptin]] – agonis reseptor μ-opioid yang lemah dan atipikal, tindakan lain&lt;br /&gt;
&lt;br /&gt;
====Hanya di luar label====&lt;br /&gt;
* [[Ketamin]] – antagonis reseptor NMDA non-kompetitif&lt;br /&gt;
* [[Pramipeksol]] - Agonis [[Reseptor (biokimia)|reseptor]] dopamin D2, D3, dan D4&lt;br /&gt;
** Agonis dopamin tidak dianjurkan karena kecenderungannya memfasilitasi perkembangan kecanduan bahkan pada individu yang tidak memiliki riwayat perilaku tersebut.&lt;br /&gt;
&lt;br /&gt;
====Dihentikan/ditarik====&lt;br /&gt;
* [[α-Metiltriptamin]] &amp;lt;nowiki&amp;gt;[&amp;lt;/nowiki&amp;gt;αMT&amp;lt;nowiki&amp;gt;]&amp;lt;/nowiki&amp;gt; – agonis reseptor serotonin non-selektif, agen pelepas serotonin-norepinefrin-dopamin (SNDRA), dan RIMA lemah&lt;br /&gt;
* [[Etriptamin]] &amp;lt;nowiki&amp;gt;[&amp;lt;/nowiki&amp;gt;α-Etiltriptamin&amp;lt;nowiki&amp;gt; (αET)]&amp;lt;/nowiki&amp;gt; – agonis reseptor serotonin non-selektif, SNDRA, dan RIMA lemah&lt;br /&gt;
* [[Indeloksazin]] – agen pelepas serotonin (SRA), NRI, dan antagonis reseptor NMDA&lt;br /&gt;
* [[Medifoksamin]] – penghambat penhambilan kembali serotonin-dopamin (SDRI) yang lemah dan antagonis reseptor 5-HT&amp;lt;sub&amp;gt;2A&amp;lt;/sub&amp;gt; dan 5-HT&amp;lt;sub&amp;gt;2C&amp;lt;/sub&amp;gt;&lt;br /&gt;
* [[Oksaflozan]] – Agonis reseptor 5-HT&amp;lt;sub&amp;gt;1A&amp;lt;/sub&amp;gt;, 5-HT&amp;lt;sub&amp;gt;2A&amp;lt;/sub&amp;gt;, dan 5-HT&amp;lt;sub&amp;gt;2C&amp;lt;/sub&amp;gt;&lt;br /&gt;
* [[Pivagabin]] – [[Mekanisme aksi|mekanisme kerja]]nya tidak diketahui/tidak jelas&lt;br /&gt;
&lt;br /&gt;
====Dijual bebas====&lt;br /&gt;
Antidepresan berikut tersedia dengan [[resep dokter]] dan dijual bebas:&lt;br /&gt;
&lt;br /&gt;
* [[Ademetionin]] &amp;lt;nowiki&amp;gt;[&amp;lt;/nowiki&amp;gt;&amp;#039;&amp;#039;S&amp;#039;&amp;#039;-Adenosil-L-metionin (SAMe)&amp;lt;nowiki&amp;gt;]&amp;lt;/nowiki&amp;gt; – [[kofaktor (biokimia)|kofaktor]] dalam [[biosintesis]] neurotransmitter monoamin&lt;br /&gt;
* &amp;#039;&amp;#039;[[Hypericum perforatum]]&amp;#039;&amp;#039; &amp;lt;nowiki&amp;gt;[&amp;lt;/nowiki&amp;gt;&amp;#039;&amp;#039;St. John&amp;#039;s Wort&amp;#039;&amp;#039;&amp;lt;nowiki&amp;gt;]&amp;lt;/nowiki&amp;gt; (Jarsin, Kira, Movina) – Aktivator TRPC6, dan berbagai tindakan lainnya&lt;br /&gt;
* [[Oksitriptan]] &amp;lt;nowiki&amp;gt;[&amp;lt;/nowiki&amp;gt;5-Hidroksitriptofan (5-HTP)&amp;lt;nowiki&amp;gt;]&amp;lt;/nowiki&amp;gt; – [[Prekursor (kimia)|prekursor]] dalam biosintesis [[serotonin]]&lt;br /&gt;
* [[Triptofan]] – prekursor dalam biosintesis serotonin&lt;br /&gt;
&lt;br /&gt;
===Perawatan tambahan===&lt;br /&gt;
====Antipsikotik atipikal====&lt;br /&gt;
* [[Aripiprazol]] – disetujui sebagai tambahan antidepresan untuk depresi berat&lt;br /&gt;
* [[Brekspiprazol]] – disetujui sebagai tambahan antidepresan untuk depresi berat&lt;br /&gt;
* [[Lumateperon]] – disetujui sebagai tambahan untuk penstabil suasana hati untuk depresi bipolar&lt;br /&gt;
* [[Lurasidon]] – disetujui sebagai tambahan untuk penstabil suasana hati untuk depresi bipolar&lt;br /&gt;
* [[Olanzapin]] – disetujui sebagai tambahan antidepresan untuk depresi berat&lt;br /&gt;
* [[Kuetiapin]] – disetujui sebagai tambahan antidepresan atau penstabil suasana hati untuk depresi berat dan depresi bipolar&lt;br /&gt;
&lt;br /&gt;
;Hanya di luar label&lt;br /&gt;
* [[Risperidon]]&lt;br /&gt;
&lt;br /&gt;
====Antipsikotik tipikal====&lt;br /&gt;
;Hanya di luar label&lt;br /&gt;
* [[Trifluoperazin]]&lt;br /&gt;
&lt;br /&gt;
====Lainnya====&lt;br /&gt;
&lt;br /&gt;
;Hanya di luar label&lt;br /&gt;
* [[Buspiron]] – Agonis parsial reseptor 5-HT&amp;lt;sub&amp;gt;1A&amp;lt;/sub&amp;gt;&lt;br /&gt;
* [[Litium (pengobatan)|Litium]] – penstabil suasana hati (mekanisme aksi tidak diketahui/tidak jelas)&lt;br /&gt;
* [[Levotiroksin]] (T&amp;lt;sub&amp;gt;4&amp;lt;/sub&amp;gt;) – [[hormon tiroid]] (agonis reseptor hormon tiroid)&lt;br /&gt;
* [[Triiodotironina]] (T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt;) – hormon tiroid (agonis reseptor hormon tiroid)&lt;br /&gt;
&lt;br /&gt;
===Obat kombinasi===&lt;br /&gt;
* [[Amitriptilin/klordiazepoksida]] – Kombinasi TCA dan [[benzodiazepin]]&lt;br /&gt;
* [[Amitriptilin/perfenazin]] – TCA dan kombinasi antipsikotik tipikal&lt;br /&gt;
* [[Flupentiksol/melitrasen]] – TCA dan kombinasi antipsikotik tipikal&lt;br /&gt;
* [[Olanzapin/fluoksetin]] – Kombinasi SSRI dan antipsikotik atipikal – disetujui sebagai monoterapi untuk depresi bipolar dan depresi yang resistan terhadap pengobatan&lt;br /&gt;
* [[Tranilsipromin/trifluoperazin]] – MAOI dan kombinasi antipsikotik tipikal&lt;br /&gt;
* [[Bupropion/dekstrometorfan]] – antagonis reseptor NMDA non-kompetitif, agonis reseptor σ&amp;lt;sub&amp;gt;1&amp;lt;/sub&amp;gt;, SNRI, NDRI, tindakan lainnya&lt;br /&gt;
&lt;br /&gt;
== Referensi ==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
== Pranala luar ==&lt;br /&gt;
&lt;br /&gt;
*&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
== Sumber dan atribusi ==&lt;br /&gt;
&lt;br /&gt;
Konten artikel ini diadaptasi dari [https://id.wikipedia.org/w/index.php?title=Antidepresan&amp;amp;oldid=29110699 Wikipedia bahasa Indonesia], revisi 29110699 (2026-04-07T11:03:24Z), yang tersedia berdasarkan lisensi Creative Commons Atribusi-BerbagiSerupa (CC BY-SA). Mohon gunakan konten ini secara bijak serta sesuai dengan ketentuan lisensi yang berlaku.&lt;/div&gt;</summary>
		<author><name>Maintenance script</name></author>
	</entry>
</feed>